Cerebral Infarction Treatment Market Size, Share & Trends Analysis Report By Type (Chemotherapy), By Drug Class (Oral), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Cerebral Infarction Treatment Market Trends

The global cerebral infarction treatment market size was estimated at USD 12.4 billion in 2023 and is projected to grow at a CAGR of 7.3% from 2024 to 2030. This growth is driven by rising prevalence of cerebrovascular diseases, advancements in medical technology, increased healthcare spending, supportive government initiatives, and an aging global population. The World Stroke Organization's Global Stroke Fact Sheet 2022 highlights that more than 7.6 million new ischemic strokes occur annually. Notably, over 58.0% of these strokes affect individuals under 70 years of age, with men representing 45.0% and women 55.0% of the cases.

The cerebral infarction treatment market is primarily driven by the increasing prevalence of cerebrovascular diseases, including ischemic stroke. According to the World Health Organization (WHO), stroke is the third leading cause of death globally, responsible for approximately 10% of all deaths. The rising incidence of risk factors such as hypertension, diabetes, obesity, and smoking further exacerbates the prevalence of cerebral infarctions. As these conditions continue to rise globally, particularly in developing countries where lifestyle changes and urbanization are rapidly occurring, the demand for effective cerebral infarction treatments is expected to grow correspondingly.

Technological advancements in neurology have significantly impacted the cerebral infarction treatment market, primarily through innovations in diagnostic and therapeutic techniques. Modern imaging technologies, such as computed tomography (CT) and magnetic resonance imaging (MRI), have greatly enhanced the early detection of cerebral infarctions, which is crucial for effective stroke management. Early and precise diagnosis facilitates timely intervention, essential for minimizing severe complications and improving survival rates.

Recent developments have also transformed the treatment of ischemic stroke. Thrombolytic therapies, such as tissue plasminogen activator (tPA) and mechanical thrombectomy devices, have revolutionized stroke care. According to the National Heart, Lung, and Blood Institute, tPA is a crucial treatment for ischemic stroke, as it dissolves blood clots obstructing brain blood flow. For optimal effectiveness, tPA should be administered within 3 hours of the onset of stroke symptoms. Research suggests that tPA may still benefit some patients if given within 4.5 hours, though this is still under investigation. These advanced treatments have been instrumental in restoring blood flow to affected brain regions, thereby reducing brain damage and enhancing patient recovery. The ongoing global adoption of these innovations is expected to drive continued growth in the cerebral infarction treatment market.

The global aging population is another critical cerebral infarction treatment market driver. As people age, the risk of stroke increases significantly. According to WHO, the global population aged 60 years and above is projected to double by 2050, reaching nearly 2.1 billion. This demographic shift is expected to result in a higher incidence of stroke, thereby driving the demand for cerebral infarction treatments. In addition, government initiatives and regulatory support have played a significant role in shaping the cerebral infarction treatment market. For instance, the American Heart Association, the Joint Commission, and the American Stroke Association introduced the Comprehensive Stroke Center (CSC) certification program, which aims to improve the quality of stroke care by certifying hospitals that meet rigorous stroke treatment and management standards. This has increased the number of specialized stroke centers nationwide, enhancing the accessibility and quality of care for stroke patients. Peripheral neuropathy is expected to account for 46.2% of the total 3000 people, chronic headaches for 26.4%, epilepsy for 8.5%, stroke for 6.6%, and tremors/disease Parkinson's for 3.8%, according to BMC Neurology study.

Market Concentration & Characteristics

The degree of innovation in cerebral infarction (stroke) treatment is marked by substantial advancements in pharmacological and non-pharmacological approaches. Recent innovations include the development of novel thrombolytics and thrombectomy devices alongside enhanced imaging techniques for better diagnosis and treatment planning. For instance, thrombolytics such as alteplase have been significantly improved, and new agents are undergoing trials to reduce stroke-related brain damage. Moreover, AI transforms stroke care by enabling early detection and risk assessment, significantly improving patient outcomes. AI-driven systems have been linked to fewer recurrent strokes, heart attacks, and vascular deaths in survivors, as reported at the American Stroke Association’s International Stroke Conference 2024. A report from the American Stroke Association highlights that innovative approaches, including mechanical thrombectomy, have increased functional independence rates in patients.

The level of M&A activity in the cerebral infarction treatment market has been notably high, reflecting the sector's attractiveness and rapid growth. Key drivers include the pursuit of cutting-edge technologies and the expansion of product portfolios. For instance, in April 2023, Genentech partnered with the University of Washington, PicnicHealth, Institute for Health Metrics and Evaluation (IHME), and Cleveland Clinic to advance brain health outcomes. This collaborative effort aims to evaluate neurological care's complexities and economic impacts on patients.

Regulations play a critical role in shaping the cerebral infarction treatment market by ensuring safety, efficacy, and quality of care. Regulatory bodies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) enforce stringent guidelines for approving and monitoring stroke treatment therapies. Recent regulatory updates have focused on expediting the approval processes for innovative stroke treatments through mechanisms such as the FDA's Breakthrough Therapy designation. For instance, the approval of new thrombectomy devices has been accelerated due to their demonstrated effectiveness in clinical trials. In addition, the Centers for Medicare & Medicaid Services (CMS) has expanded coverage for specific stroke treatments, reflecting a regulatory trend toward supporting advanced, cost-effective care. These regulatory frameworks ensure that new treatments are safe and accessible while encouraging ongoing research and development.

Regional expansion in the cerebral infarction treatment market is driven by increasing stroke prevalence and growing healthcare infrastructure in emerging markets. Countries in Asia-Pacific and Latin America are experiencing rising stroke rates due to aging populations and lifestyle factors. For instance, India has seen a surge in stroke care facilities and advanced treatment options as part of its commitment to improving healthcare outcomes. Expanding stroke care services and establishing specialized centers in these regions are expected to enhance treatment accessibility and outcomes, contributing to a growing market presence.

For instance, in September 2023, Sun Pharmaceutical Industries Limited announced a licensing agreement with U.S. biopharmaceutical company Pharmazz Inc. Under this agreement, Sun Pharma's subsidiary will commercialize Tyvalzi (Sovateltide) in India. Sovateltide, an innovative drug developed by Pharmazz, is designed to treat cerebral ischemic stroke. The agreement grants Sun Pharma exclusive rights to market this first-in-class medication in the Indian market, where it will be branded as Tyvalzi. This collaboration aims to bring advanced treatment options to patients in India. This expansion trend is driven by the increasing demand for integrated stroke management solutions and the competitive landscape among major players aiming to leverage synergies and accelerate innovation.

Type Insights

In 2023, the ischemic stroke segment held the largest share of 78.6% due to its high prevalence, technological advancements, and growing awareness of early intervention. According to the World Stroke Organization's 2022 Global Stroke Fact Sheet, ischemic strokes-caused by blocked blood flow to the brain-are the most common, making up around 62% of all stroke cases globally, with 3.3 million annual deaths. Developing and adopting advanced treatment options such as thrombolytic therapies and mechanical thrombectomy devices fuels the market's growth. Thrombolytics such as tissue plasminogen activator (tPA) have been the cornerstone of ischemic stroke treatment, significantly improving outcomes when administered within the therapeutic frame.

The hemorrhagic stroke segment is experiencing the fastest-growing CAGR of 8.2% within the cerebral infarction treatment market, driven by its high mortality and morbidity rates despite being less common than ischemic strokes. Hemorrhagic strokes occur when a brain blood vessel ruptures, causing bleeding in or around the brain. According to the World Stroke Organization's 2022 Global Stroke Fact Sheet, over 3.4 million new intracerebral hemorrhages occur annually, with nearly 3 million resulting in death. The growing global burden of hypertension, a significant risk factor for hemorrhagic strokes, has led to an increase in the incidence of these strokes, particularly in low- and middle-income countries.

Drug Class Insights

The tissue plasminogen activators (tPA) segment secured the largest revenue share of 39.7% in 2023, driven by its proven efficacy, widespread use, and crucial role in treating ischemic strokes. Since its FDA approval in 1996, tPA, especially alteplase, has been the gold standard for acute ischemic stroke management. The 2020 American Heart Association guidelines reaffirmed tPA's importance, recommending its use in eligible patients. tPA works by dissolving blood clots, restoring blood flow to the brain, and reducing the risk of long-term disability. The American Stroke Association highlights the need for tPA administration within 3 to 4.5 hours of stroke onset, influencing global hospital protocols and emergency response strategies and cementing its role as an essential stroke treatment.

Anticoagulants are anticipated to achieve the highest CAGR of 9.0% during the forecast period, driven by their expanding role in stroke prevention, particularly among patients with atrial fibrillation (AF). The rising prevalence of AF, a significant risk factor for ischemic strokes, underscores this growth. The American Heart Association estimates that AF will impact 12.1 million people in the U.S. alone, with numbers increasing due to an aging population. AF elevates the risk of blood clots forming in the heart, potentially leading to strokes. By thinning the blood, anticoagulants reduce the risk of clot formation, making them essential for stroke prevention in AF patients. Advancements in anticoagulant therapies further bolster their adoption, positioning them as a critical component in managing stroke risk.

The introduction of novel oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban has significantly transformed stroke prevention strategies. These NOACs offer notable improvements over traditional vitamin K antagonists, such as warfarin, by providing fewer dietary restrictions, reduced monitoring requirements, and a lower risk of intracranial bleeding. Clinical trials have consistently shown that NOACs are at least as effective as warfarin in stroke prevention, with some studies indicating better outcomes in specific patient groups. Moreover, growing awareness and updated clinical guidelines are accelerating the adoption of NOACs. Leading medical bodies, including the European Society of Cardiology and the American College of Cardiology, have revised their policies to prioritize NOACs over warfarin for most patients with atrial fibrillation, further enhancing their market presence and acceptance.

Distribution Channel Insights

In 2023, the hospital pharmacies segment dominated the cerebral infarction treatment market, capturing a substantial revenue share of 63.6%. This leadership position is attributed to hospital pharmacies' crucial role in the acute management of stroke patients, the rising incidence of stroke, and the centralized distribution of specialized medications. Hospital pharmacies are vital in delivering immediate and specialized care during the critical early phase of stroke treatment. According to the Australian Institute of Health and Welfare, there were approximately 67,900 hospitalizations in 2020-21, where stroke was the principal diagnosis, equating to a rate of 265 per 100,000 people. These cases accounted for 0.6% of all hospitalizations and 11.0% of cardiovascular disease (CVD) hospitalizations in Australia, given the urgent nature of stroke treatment-where interventions such as thrombolytics, such as tissue plasminogen activators (tPA), must be administered within a narrow window of time where hospital pharmacies are essential for the timely dispensing of these life-saving medications.

Retail pharmacies are anticipated to achieve the highest CAGR of 9.6% during the forecast period. This growth is attributed to the patient's preference for convenience and the expansion of accessible healthcare services through retail channels. The trend toward patient-centered care and the increasing emphasis on medication adherence has prompted retail pharmacies to expand their services. Many retail pharmacies now offer medication therapy management (MTM) services, where pharmacists provide counseling and monitor patients' medication regimens, ensuring adherence and optimizing therapeutic outcomes. This personalized care model is becoming increasingly important as healthcare systems aim to reduce hospital readmissions and improve long-term health outcomes for stroke patients.

Regional Insights

North America leads the global cerebral infarction treatment market 39.54% in 2023, driven by its advanced healthcare infrastructure, high stroke prevalence, and substantial investments in research and development. According to a CDC report from May 2024, stroke ranks as the fifth leading cause of death in the U.S., with around 795,000 cases annually. In 2022, strokes accounted for 17.5% of cardiovascular disease deaths in the country. This high incidence drives the demand for sophisticated treatment options, including tissue plasminogen activators (tPA) and mechanical thrombectomy devices. Supportive reimbursement policies and robust government backing for stroke research, such as funding from the National Institutes of Health (NIH), further stimulate market growth.

U.S. Cerebral Infarction Treatment Market Trends

The cerebral infarction treatment market in the U.S. is characterized by its technological advancements and emphasis on personalized medicine. The country is at the forefront of adopting innovative therapies, including new anticoagulants and AI-powered diagnostic tools. According to estimates from the Georgia Department of Public Health in April 2024, stroke is the fifth leading cause of death in Georgia and a major, yet preventable, cause of disability. Georgia, located in the "stroke belt" of the southeastern U.S., experiences stroke death rates approximately 30.0% higher than the national average. The coastal plains of Georgia, known as the "buckle" of this region, face stroke death rates about 40.0% higher than the rest of the country.

Europe Cerebral Infarction Treatment Market Trends

The cerebral infarction treatment market in Europe is proliferating due to the aging population, increasing incidence of stroke, and supportive healthcare policies. The European Society of Cardiology highlights that stroke is a leading cause of disability and mortality in Europe, with over 1.1 million new strokes occurring annually. The European Union’s investments in healthcare infrastructure and the adoption of integrated stroke care pathways, such as the Stroke Action Plan for Europe 2018 - 2030, are key market growth drivers. The region’s emphasis on early intervention and rehabilitation has also increased the demand for advanced stroke treatments.

The cerebral infarction treatment market in the UK is expected to grow during the forecast period. The robust national healthcare system and comprehensive stroke management programs bolster the cerebral infarction treatment market in the UK. The National Health Service (NHS) has implemented the National Stroke Strategy, which focuses on improving stroke prevention, acute care, and rehabilitation services. The UK’s commitment to reducing stroke-related mortality and morbidity has led to significant investments in advanced therapies, including thrombectomy services, which are now widely available across major NHS hospitals. Furthermore, the UK’s participation in European and global stroke research initiatives has enhanced access to innovative treatments, supporting market growth.

France Cerebral infarction market is expected to expand with decent CAGR during the forecast period. The country’s well-established healthcare infrastructure and proactive public health policies strongly support the cerebral infarction treatment market in France. France has one of the highest incidences of stroke in Europe, with over 150,000 new cases annually, driving demand for effective treatments. As the National Stroke Plan outlines, the French government’s focus on stroke prevention and care includes widespread access to emergency stroke units and advanced therapies such as tPA and thrombectomy. In addition, France’s active involvement in clinical trials and research collaborations has accelerated the adoption of innovative treatments, contributing to market expansion.

Asia Pacific Cerebral Infarction Treatment Market Trends

The cerebral infarction treatment market in the Asia Pacific region is expanding rapidly due to increasing stroke incidence, higher healthcare investments, and growing awareness about stroke prevention and treatment. Countries such as China and India are experiencing a rise in stroke cases driven by aging populations and lifestyle changes. The World Health Organization (WHO) forecasts a significant increase in stroke-related morbidity in the region. A study published by the National Library of Medicine in April 2024 highlights that Asia, with an estimated population of 4.7 billion in 2023, faces a substantial health challenge, with between 9.5 and 10.6 million stroke cases annually. In addition, data from the Australian Bureau of Statistics reveals that in 2022, 5.2% (1.3 million) of Australians had heart, stroke, and vascular disease. The region's healthcare burden is further complicated by uneven resource distribution across its well-developed and developing nations, leading to notable disparities in stroke care and management.

The cerebral infarction treatment market in India is experiencing rapid growth, fueled by an increasing prevalence of stroke and expanding healthcare infrastructure. India records approximately 1.8 million strokes annually, with stroke being a leading cause of disability. Government initiatives such as the National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases & Stroke (NPCDCS) are focused on enhancing stroke care services, including establishing stroke units and public awareness campaigns. The growing adoption of telemedicine and mobile health technologies also improves access to stroke treatment in remote areas, contributing to market expansion.

China cerebral infarction treatment market in is significantly influenced by the country’s large aging population, increasing incidence of stroke, and government-led healthcare reforms. China accounts for nearly one-third of the global stroke burden, with approximately 2.5 million new stroke cases annually. The Chinese government has launched several initiatives, such as the National Stroke Screening Survey, aimed at early detection and prevention of stroke. In addition, investments in modernizing healthcare infrastructure, including developing stroke centers and adopting advanced treatment technologies, are driving growth in the Chinese market.

Latin America Cerebral Infarction Treatment Market Trends

The cerebral infarction treatment market in Latin America is expanding due to increasing healthcare investments, rising stroke prevalence, and efforts to improve access to advanced treatments. Stroke is a leading cause of death and disability in Latin America, with the Pan American Health Organization (PAHO) emphasizing the need for better stroke care. Governments across the region are investing in healthcare infrastructure, particularly in urban centers, to provide timely and effective stroke treatment. In addition, the growing presence of multinational pharmaceutical companies is improving access to innovative therapies, further driving market growth.

A high burden of stroke drives the cerebral infarction treatment market in Brazil, government initiatives to enhance stroke care, and the expansion of healthcare services. According to the National Library of Medicine, Brazil has one of the highest stroke rates in Latin America, with approximately 400,000 strokes occurring annually. The Brazilian government has implemented national health policies to improve stroke prevention, acute care, and rehabilitation services. The establishment of specialized stroke centers and the adoption of telemedicine are enhancing access to treatment, particularly in rural areas. These efforts and increasing public awareness are propelling market growth in Brazil.

Middle East & Africa Cerebral Infarction Treatment Market Trends

The cerebral infarction treatment market in the Middle East and Africa is witnessing significant growth driven by rising stroke incidence, improving healthcare infrastructure, and increasing government focus on non-communicable diseases. Governments in the Middle East, particularly in countries such as Saudi Arabia and the UAE, are investing in advanced healthcare facilities and public health campaigns to address stroke prevention and treatment. In addition, international collaborations and investments in medical research are supporting market growth.

Saudi Arabia cerebral infarction treatment market in is rapid healthcare advancements, government-led initiatives, and a rising burden of stroke characterize the cerebral infarction treatment market in Saudi Arabia. Under its Vision 2030 plan, the Saudi Arabian government is prioritizing the enhancement of healthcare services, including the management of non-communicable diseases such as stroke. The Ministry of Health has established stroke centers and implemented national stroke guidelines to improve patient outcomes.

Key Cerebral Infarction Treatment Company Insights

The cerebral infarction treatment market is dominated by several major pharmaceutical companies that collectively account for a significant market share. These leading players established themselves through extensive R&D efforts, resulting in the introduction of innovative treatment options. They also expanded their product portfolios through strategic collaborations, mergers, and acquisitions. 

Recent Developments

• In June 2024, Siemens Healthineers and the World Stroke Organization (WSO) launched a two-year global partnership to enhance the acute stroke workforce and advance treatment and care. This collaboration will focus on low- and middle-income countries, providing structured education and training programs to address stroke as a critical global healthcare issue.

• In June 2024, Cerenovus, Inc., a Johnson & Johnson MedTech division, introduced new initiatives to address racial and ethnic disparities in stroke treatment. The company unveiled an online Digital Health Equity Hub featuring published research and interactive tools. This platform is intended to support hospital leaders in developing and implementing strategies to reduce disparities in stroke care and track their progress in improving health equity across the continuum of care.

• In March 2024, the U.S. FDA approved a new use for Wegovy (semaglutide) to reduce the risk of heart attack, cardiovascular death, and stroke in adults with cardiovascular disease who are obese or overweight. This approval underscores the importance of integrating Wegovy with a reduced-calorie diet and increased physical activity.

• In February 2024, Aruna Bio, a biotechnology company specializing in neural exosomes for neurodegenerative diseases, announced a Phase I/II clinical trial for AB126, an allogeneic neural exosome derived from neural stem cells. The trial will assess AB126's safety, tolerability, and initial efficacy in ischemic stroke patients who have a poor prognosis after thrombectomy. This study evaluates a novel treatment approach for challenging post-stroke recovery cases.

• In December 2023, the Evelyn F. and William L. McKnight Brain Institute launched a USD 1 million AI-driven project to enhance stroke treatment, backed by University of Florida President Ben Sasse's strategic funding initiative. This effort aims to improve diagnostic accuracy, personalize care, and advance stroke patient outcomes.

• In October 2023, Australian biotechnology firm Argenica Therapeutics received approval from St Vincent's Hospital Melbourne's Human Research Ethics Committee (HREC) to advance ARG-007 into Phase II clinical trials. This novel treatment aims to protect brain cells from damage in patients with acute ischemic stroke (AIS).

• In October 2023, Royal Philips, a global leader in health technology, and the World Stroke Organization (WSO), the premier global NGO dedicated to stroke, announced a two-year partnership. This collaboration is designed to enhance access to high-quality stroke care worldwide, leveraging Philips' technological expertise and WSO's commitment to stroke advocacy to improve treatment and outcomes for stroke patients.

Cerebral Infarction Treatment Market Report Scope

Global Cerebral Infarction Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global cerebral infarction treatment market report based on type, drug class, distribution channel, and region.

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Ischemic Stroke

  • Hemorrhagic Stroke

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

  • Tissue Plasminogen Activators (tPA)

  • Anticoagulants

  • Antiplatelets

  • Anticonvulsants

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Other

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait